Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> VEGFR

VEGFR

VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases.

Products for  VEGFR

  1. Cat.No. Product Name Information
  2. GC13944 (5Z)-7-Oxozeaenol

    TAK1 mitogen-activated protein kinase kinase kinase (MAPKKK) inhibitor

     (5Z)-7-Oxozeaenol Chemical Structure
  3. GC17800 (E)-FeCP-oxindole VEGFR-2 inhibitor (E)-FeCP-oxindole Chemical Structure
  4. GC13344 (Z)-FeCP-oxindole VEGFR-2 inhibitor (Z)-FeCP-oxindole Chemical Structure
  5. GC62291 (Z)-Orantinib (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 ?M, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors. (Z)-Orantinib Chemical Structure
  6. GC33087 2,4-Pyrimidinediamine with linker 2,4-Pyrimidinediamine with linker is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69. 2,4-Pyrimidinediamine with linker Chemical Structure
  7. GC25017 4,4'-Bis(4-aminophenoxy)biphenyl 4,4'-Bis(4-aminophenoxy)biphenyl is a monomer for polyimide production. 4,4'-Bis(4-aminophenoxy)biphenyl Chemical Structure
  8. GC63805 4SC-203 4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs. 4SC-203 Chemical Structure
  9. GC10938 AAL-993 VEGF receptors inhibitor AAL-993 Chemical Structure
  10. GC30242 Acrizanib Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2. Acrizanib Chemical Structure
  11. GC15801 ACTB-1003 ACTB-1003 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2. ACTB-1003 Chemical Structure
  12. GC68628 Aflibercept

    Aflibercept (VEGF Trap) is a soluble decoy VEGFR composed of Ig domains from VEGFR1 and VEGFR2 fused to the Fc domain of human IgG1. Aflibercept inhibits the VEGF signaling pathway by blocking pathways regulated by VEGF. Aflibercept can be used in research for age-related macular degeneration (AMD) and cardiovascular diseases.

     Aflibercept Chemical Structure
  13. GC35263 AG-13958 AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD). AG-13958 Chemical Structure
  14. GC16604 Altiratinib c-MET/TIE-2/VEGFR inhibitor Altiratinib Chemical Structure
  15. GC14292 Apatinib Mesylate

    Apatinib blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization.

     Apatinib Mesylate Chemical Structure
  16. GC10914 AST 487 A multi-kinase inhibitor AST 487 Chemical Structure
  17. GC12216 Axitinib (AG 013736) Axitinib (AG 013736) is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. Axitinib (AG 013736) Chemical Structure
  18. GC62185 Axitinib-d3 Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. Axitinib-d3 Chemical Structure
  19. GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit AZD2932 Chemical Structure
  20. GC11726 BAW2881 (NVP-BAW2881) BAW2881 (NVP-BAW2881) (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC50 of 4 nM. BAW2881 (NVP-BAW2881) Chemical Structure
  21. GC34216 Bevacizumab (Anti-Human VEGF, Humanized Antibody) Bevacizumab (Anti-Human VEGF, Humanized Antibody), a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity. Bevacizumab (Anti-Human VEGF, Humanized Antibody) Chemical Structure
  22. GC15340 BFH772 VEGFR2 inhibitor BFH772 Chemical Structure
  23. GC35516 BIBF 1202 BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM. BIBF 1202 Chemical Structure
  24. GC50330 BMS 605541 Potent VEGFR-2 inhibitor BMS 605541 Chemical Structure
  25. GC13873 BMS-690514 BMS-690514 Chemical Structure
  26. GC13833 BMS-794833 Met/VEGFR-2 inhibitor,potent and ATP-competitive BMS-794833 Chemical Structure
  27. GC11692 Brivanib (BMS-540215) Brivanib (BMS-540215) (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Brivanib (BMS-540215) Chemical Structure
  28. GC14238 Brivanib Alaninate (BMS-582664) Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ. Brivanib Alaninate (BMS-582664) Chemical Structure
  29. GC15779 Cabozantinib (XL184, BMS-907351) Cabozantinib (XL184, BMS-907351) is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib (XL184, BMS-907351) displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib (XL184, BMS-907351) shows antiangiogenic activity. Cabozantinib (XL184, BMS-907351) disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis. Cabozantinib (XL184, BMS-907351) Chemical Structure
  30. GC12531 Cabozantinib malate (XL184) Cabozantinib malate (XL184) (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. Cabozantinib malate (XL184) Chemical Structure
  31. GC67948 Cabozantinib-d6 Cabozantinib-d6 Chemical Structure
  32. GC16421 Cediranib (AZD217) Cediranib (AZD217) (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib (AZD217) Chemical Structure
  33. GC33004 Cediranib maleate (AZD-2171 maleate) Cediranib maleate (AZD-2171 maleate) (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib maleate (AZD-2171 maleate) Chemical Structure
  34. GC14650 CGP60474 A CDK inhibitor CGP60474 Chemical Structure
  35. GC62145 Chiauranib Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects. Chiauranib Chemical Structure
  36. GC32979 Chloropyramine hydrochloride Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK. Chloropyramine hydrochloride Chemical Structure
  37. GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF CP-547632 Chemical Structure
  38. GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy. CP-547632 hydrochloride Chemical Structure
  39. GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy. CP-547632 TFA Chemical Structure
  40. GC12980 CP-673451 PDGFRα/β inhibitor,potent and selective CP-673451 Chemical Structure
  41. GC17098 DMH4 VEGFR-2 inhibitor DMH4 Chemical Structure
  42. GC10165 Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib (TKI258) Lactate Chemical Structure
  43. GC11372 Dovitinib Dilactic acid FLT3 inhibitor Dovitinib Dilactic acid Chemical Structure
  44. GC12149 E-3810 E-3810 Chemical Structure
  45. GC16183 EG00229

    Nrp1 inhibitor

     EG00229 Chemical Structure
  46. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076 Chemical Structure
  47. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid Chemical Structure
  48. GC64836 Famitinib Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis. Famitinib Chemical Structure
  49. GC15735 Foretinib (GSK1363089) Foretinib (GSK1363089) is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. Foretinib (GSK1363089) Chemical Structure
  50. GC10355 Fruquintinib(HMPL-013) Fruquintinib(HMPL-013) (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively. Fruquintinib(HMPL-013) Chemical Structure
  51. GC17715 Golvatinib (E7050) Golvatinib (E7050) (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively. Golvatinib (E7050) Chemical Structure
  52. GC36203 GW806742X GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X Chemical Structure
  53. GC61454 GW806742X hydrochloride GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis. GW806742X hydrochloride Chemical Structure
  54. GC32963 hVEGF-IN-1 hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression. hVEGF-IN-1 Chemical Structure
  55. GC43885 Hypothemycin A resorcylic acid lactone polyketide Hypothemycin Chemical Structure
  56. GC34159 Ilorasertib (ABT-348) Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib (ABT-348) Chemical Structure
  57. GC38519 Ilorasertib hydrochloride Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib hydrochloride Chemical Structure
  58. GC18168 JI-101

    An orally active inhibitor

     JI-101 Chemical Structure
  59. GC32625 KDR-in-4 KDR-in-4 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM. KDR-in-4 Chemical Structure
  60. GC13264 Ki20227 A c-Fms kinase inhibitor Ki20227 Chemical Structure
  61. GC11666 Ki8751 VEGFR-2 inhibitor,potent and selective Ki8751 Chemical Structure
  62. GC12590 KRN 633 VEGFR inhibitor,ATP-competitive KRN 633 Chemical Structure
  63. GC15454 Lenvatinib (E7080) Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. Lenvatinib (E7080) Chemical Structure
  64. GC36438 Lenvatinib mesylate An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate Chemical Structure
  65. GC17958 Linifanib (ABT-869) Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. Linifanib (ABT-869) Chemical Structure
  66. GC13848 LY2784544 Potent inhibitor of JAK2 LY2784544 Chemical Structure
  67. GC16483 MAZ51 VEGFR3 antagonist MAZ51 Chemical Structure
  68. GC13598 MGCD-265 MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity. MGCD-265 Chemical Structure
  69. GC13012 Motesanib Motesanib Chemical Structure
  70. GC11336 Motesanib Diphosphate (AMG-706) Motesanib Diphosphate (AMG-706) (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret. Motesanib Diphosphate (AMG-706) Chemical Structure
  71. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide Chemical Structure
  72. GC18211 Ningetinib A multi-kinase inhibitor Ningetinib Chemical Structure
  73. GC36744 Ningetinib Tosylate Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib Tosylate Chemical Structure
  74. GC36745 Nintedanib esylate

    Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability .

     Nintedanib esylate Chemical Structure
  75. GC34126 NVP-ACC789 (ACC-789) NVP-ACC789 (ACC-789) is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. NVP-ACC789 (ACC-789) Chemical Structure
  76. GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment. ODM-203 Chemical Structure
  77. GC32502 Oglufanide (H-Glu-Trp-OH) Oglufanide (H-Glu-Trp-OH) (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide (H-Glu-Trp-OH) Chemical Structure
  78. GC14957 OSI-930 Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck OSI-930 Chemical Structure
  79. GC69662 Parsatuzumab

    Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody that binds to EGFL7 as an immune modulator. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, which may inhibit angiogenesis and reduce the inhibition of vascular endothelial growth factor (VEGF).

     Parsatuzumab Chemical Structure
  80. GC16327 Pazopanib (GW-786034) A multi-kinase inhibitor Pazopanib (GW-786034) Chemical Structure
  81. GC12730 Pazopanib Hydrochloride VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor Pazopanib Hydrochloride Chemical Structure
  82. GC64346 Pegaptanib sodium Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib sodium Chemical Structure
  83. GC60283 Pentagamavunon-1 Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF). PGV-1 inhibits NF-κB activation. Pentagamavunon-1 Chemical Structure
  84. GC18074 PF-03814735 An inhibitor of Aurora A and B kinases PF-03814735 Chemical Structure
  85. GC14396 Ponatinib (AP24534) Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534) Chemical Structure
  86. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib Ponatinib-d8 Chemical Structure
  87. GC11003 PP121 Dual inhibitor of tyrosine and phosphoinositide kinases PP121 Chemical Structure
  88. GC65335 PTC299 PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies. PTC299 Chemical Structure
  89. GC37047 Pz-1 Pz-1 is a potent RET and VEGFR2 inhibitor with IC50s of less than 1 nM for both wild type kinases. Pz-1 Chemical Structure
  90. GC12857 R1530 A multi-kinase inhibitor R1530 Chemical Structure
  91. GC33271 R916562 R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis. R916562 Chemical Structure
  92. GC15818 RAF265 Multiple intracellular kinases inhibitor RAF265 Chemical Structure
  93. GC19534 Ramucirumab

    Ramucirumab is a fully human monoclonal antibody (IgG1).

     Ramucirumab Chemical Structure
  94. GC14606 Regorafenib hydrochloride A multi-kinase inhibitor Regorafenib hydrochloride Chemical Structure
  95. GC14534 Regorafenib monohydrate A multi-kinase inhibitor Regorafenib monohydrate Chemical Structure
  96. GC64895 Regorafenib-d3 Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor. Regorafenib-d3 Chemical Structure
  97. GC37538 Ripretinib Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis. Ripretinib Chemical Structure
  98. GC12586 SAR131675

    VEGFR3 inhibitor,selective and ATP-competitve

     SAR131675 Chemical Structure
  99. GC19108 SCR-1481B1 SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor. SCR-1481B1 Chemical Structure
  100. GC19332 Sitravatinib Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/L. Sitravatinib Chemical Structure
  101. GC13738 SKLB1002 VEGFR2 inhibitor,potent and ATP-competitve SKLB1002 Chemical Structure

Items 1 to 100 of 163 total

per page
  1. 1
  2. 2

Set Descending Direction